financetom
Business
financetom
/
Business
/
Avicanna Fully Repays Debentures
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Avicanna Fully Repays Debentures
Aug 31, 2024 11:30 PM

08:28 AM EDT, 08/30/2024 (MT Newswires) -- Avicanna ( AVCNF ) said Friday that it has cleared and fully repaid about $1.445 million owed under its debentures dated Aug. 2, 2023.

Avicanna ( AVCNF ) is a biopharmaceutical company focused on developing plant-derived cannabinoid-based products.

The company's share price fell 2.6% yesterday to $0.38.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Top Premarket Decliners
Top Premarket Decliners
Sep 9, 2024
07:56 AM EDT, 09/09/2024 (MT Newswires) -- Wheeler REIT (WHLR) shares slumped 23% pre-bell Monday, paring Friday's rally. C4 Therapeutics ( CCCC ) shares dropped 17%, adding to a 7.4% loss in the previous session. SmartKem ( SMTK ) shares were down 11%, reversing from Friday's gains. Price: 7.89, Change: -2.36, Percent Change: -23.02 ...
Teekay Launches $40 Million Buyback Program
Teekay Launches $40 Million Buyback Program
Sep 9, 2024
07:56 AM EDT, 09/09/2024 (MT Newswires) -- Teekay ( TK ) said Monday that its board has authorized a new share buyback program for the repurchase of up to $40 million common stock. The shipping company said it has nearly completed a previous $25 million repurchase program initiated in August 2022, buying back about 3.3 million shares at an average...
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Sep 9, 2024
Sunday, Summit Therapeutics Inc. ( SMMT ) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc. The data was presented at the International Association for the Study of Lung Cancer’s 2024 World Conference on Lung Cancer. The trial evaluated monotherapy ivonescimab against monotherapy Merck ( MRK...
Top Premarket Gainers
Top Premarket Gainers
Sep 9, 2024
07:56 AM EDT, 09/09/2024 (MT Newswires) -- Intelligent Bio Solutions ( INBS ) shares surged more than 68% pre-bell Monday, extending Friday's rally. Summit Therapeutics ( SMMT ) shares advanced more than 31% after the company reported that a phase 3 trial of ivonescimab demonstrated significantly improved progression-free survival in patients with non-small cell lung cancer. Terns Pharmaceuticals ( TERN...
Copyright 2023-2026 - www.financetom.com All Rights Reserved